Phenolphthalein Method as a Simple and Low Cost Test for Detection of Fecal Occult Blood
|
|
- Stuart Fitzgerald
- 6 years ago
- Views:
Transcription
1 British Journal of Medicine & Medical Research 22(2): 1-6, 2017; Article no.bjmmr ISSN: , NLM ID: Phenolphthalein Method as a Simple and Low Cost Test for Detection of Fecal Occult Blood Seyedeh Maryam Sharafi 1, Azar Balouti 2, Mahboobeh Hadipour 2, Hajar Yazdani 2, Morteza Yousefi 3 and Hossein Yousofi Darni 4* 1 Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. 2 Department of Medical Parasitology and Mycology, Isfahan University of Medical Sciences, Isfahan, Iran. 3 Department of Surgery, Kurdistan University of Medical Sciences, Sanandaj, Iran. 4 Cancer Prevention Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran. Authors contributions This work was carried out in collaboration between all authors. Author SMS performed some lab work and also helped for preparation of the first draft of the paper. Authors AB, MH and HY collected the samples and helped with the performance of lab works. Author MY contributed to the designing of research work and also preparation of the paper. Author HYD designed the research and supervised the lab works and also finalized preparation of the paper. All authors read and approved the final manuscript. Article Information DOI: /BJMMR/2017/34677 Editor(s): (1) Mohammed Rachidi, Molecular Genetics of Human Diseases, French Polynesia, University Paris 7 Denis Diderot, Paris, France. (2) Gentian Vyshka, University of Medicine in Tirana, Albania. Reviewers: (1) Cletus Anes Ukwubile, Federal Polytechnic, Nigeria. (2) Somchai Amornyotin, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand. Complete Peer review History: Original Research Article Received 5 th June 2017 Accepted 19 th July 2017 Published 26 th July 2017 ABSTRACT Background: Colorectal cancer is one of the main causes of cancer related death worldwide. Different investigation showed that screening with fecal occult blood is able to reduce incidence of colorectal cancer in a given area. To provide a simple and cost effective test for screening of colorectal cancer in this work sensitivity of phenolphthalein method in detection of occult blood has been investigated. Methods: In this descriptive study alcohol pyramidon and phenolphthalein methods were used to estimate the minimum amount of human occult blood which can be detected in distilled water and *Corresponding author: yousofidarani@gmail.com;
2 fecal samples. Then 100 fecal samples were examined by the two tests. Results: Alcohol pyramidon method detected minimum amount of µl blood in 1 ml distilled water while phenolphthalein methods detected minimum amount of µl blood in 1 ml distilled water. In another experiment Alcohol pyramidon method detected minimum amount of 1 µl blood in 1 ml fecal sample while phenolphthalein methods detected minimum amount of 0.25 µl blood in about 1 ml fecal sample. Phenolphthalein method provided more positive results when 100 fecal samples were tested. Conclusion: phenolphthalein method is a sensitive, simple and economy test for colorectal cancer screening which can be used both in labs and at home. Keywords: Colorectal cancer; occult blood; screening; phenolphthalein method. 1. INTRODUCTION Colorectal cancer is one of the leading causes of cancer-related deaths in the United States. Screening by means of fecal occult-blood testing leads to reduction of mortality and incidence of colorectal-cancer [1]. Fecal occult blood and its constituent, fecal occult hemoglobin, is the most abundant component associated with colorectal lesions, so positive fecal occult blood tests may be a good marker for discovery of early colorectal cancers [2-6]. About four decades ago fecal occult blood test was introduced to screen for colorectal cancer [7,8]. After that in several investigations it t has been shown that screening for fecal occult blood significantly reduce the rate of death from colorectal cancer [9-13]. Also screening with fecal occult-blood test, significantly reduces the incidence of colorectal cancer [14]. Fecal occult blood test is able to detect large polyps which are more likely to bleed [15-17] and also to become cancerous [18]. Chemical fecal occult bold tests are not specific for human blood [7]. In condition of dietary constituent with sufficient peroxidase activity they may give false positive results [19]. On the other hand various chemicals may interfere with the test and lead to providing false negative results [20,21]. However, they are is still the most implemented test for colorectal cancer screening [14]. Chemical tests such as guaiac [22], benzidine [23], Tetra-p-bhenylenediamine & hydrochloride [24] were used for detection of fecal occult blood. These tests are not specific for human blood [25]. To overcome the problem of non-specificity immunochemical fecal occult blood tests were introduced. These tests seem to have higher specificity compared with chemical tests [22]. Although chemical tests for detection of occult blood are not specific for human blood, they are still the most implemented test for colorectal cancer screening [14]. In order to present a sensitive, simple and economy chemical test for detection of fecal occult blood, in this work sensitivity of phenolphthalein method has been investigated. 2. MATERIALS AND METHODS In this study, 30 spare blood and 60 fecal samples were collected with patients informed consent from Alzahra hospital diagnostic lab in Isfahan, Iran (This work was approved by Research Ethic committee of Isfahan University of medical sciences). In order to test the sensitivity of the alcohol pyramidon or phenolphthalein methods, in 5 transparent glass test tubes 1mL distilled water was added. Then 2, 1, 0.5, 0.25 and µl blood was added into tubes 1-5. In the next step both alcohol pyramidon or phenolphthalein methods were performed for the above five tubes and the results were recorded. In the next experiment again to five test tubes, 3 ml distilled water and about 1 ml stool sample was added to each tube. Then 2, 1, 0.5, 0.25 and µl blood was added to tubes 1-5 respectively and both alcohol pyramidon or phenolphthalein methods were performed for the above five tubes and the results were recorded. 2.1 Alcohol Pyramidon Method Alcohol byramidon reagent was prepared by adding 5 gram powder of this alcohol to 100 ml distilled water and mixed well. Other reagents were 10% acetic acid and 5% H 2 O 2. To perform the test, to test tubes containing diluted fecal samples in distilled water equal volume of Alcohol pyramidon reagent was added and mixed well. After that 5 drops of 10% acetic acid was added and mixed again. Finally, 5 drops of 5% H 2 O 2 was added and appearance of the purple color was monitored. According to the intensity of the purple color positive results recorded as 1+ to 4+. 2
3 2.2 Phenolphthalein Method To make phenolphthalein reagent, 1 gram phenolphthalein powder and 25 g KOH were dissolved in 100 ml distilled water. The resulting red solution was boiled and 10 g zinc powder was added to get a colorless solution. The reagent was then filtered and equal volume of 96% alcohol was added. In order to perform the test, 5 drops of phenolphthalein reagent was added to tubes containing stool sample in distilled water and mixed. In the last stage 5drops of H 2 O 2 was added and appearance of red color was monitored. According to the intensity of the red color positive results recorded as 1+ to RESULTS Experiment 1: To 7 transparent glass test tubes 1ml distilled water was poured and 2, 1, 0.5, 0.25, 0.125, and µl blood sample was added to tubes 1-7 respectively. In the next step alcohol pyramidonand phenolphthaleinmethods were performed on all above tubes. Results of this experiment has been summarized in Table 1. Experiment 2: In 5 test tubes about 1ml stool sample was mixed with 3mls distilled water and then 2, 1, 0.5, 0.25 and µl blood samples was added to tubes 1-5 respectively. In the next step phenolphthalein and alchoholpyramidon methods were performed on all above tubes. Results of this experiment has been summarized in Table 2. Experiment 3: one hundred spare stool samples with order for occult blood test were examined both by alcohol pyramidon and phenolphthalein methods. The results have been summarized in Table DISCUSSION Results of this work showed that phenolphthalein method detected as less as about 0.03 µl blood in 1 ml distilled water. Also this test detected 0.24 µl blood in mixture of 3 ml distilled water and 1 ml feces. This indicates that the test detected about 0.06 µl blood in 1 ml of stool. So it seems that phenolphthalein is a very sensitive test for detection of occult blood in stool samples. Beside sensitivity, other advantage of this test is its simplicity. To perform this test what we need is a 5 ml glass tube, phenolphthalein reagent and H 2 O 2. So it is possible to present this test in a simple kit which can be used in medical diagnostic labs and also at home by people older than 50 who want to screen themselves for colorectal cancers. Several factors such as the diet of the patient may influence the result of the occult blood test and lead to providing false negative results [20,21]. On the other hand these factors may also provide false positive results and this is a common problem with using all chemical occult blood tests. Because phenolphthalein occults blood test is very simple and easy to do and also cost effective, with the repetition of the test it is possible to overcome false positive or false negative results. Table 1. Results of alcohol pyramidin or phenolphthalein for test tubes containing 2, 1, 0.5, 0.25, 0.125, and µl blood sample in 1 ml distilled water Amount of blood 2 µl 1 µl 0.5 µl 0.25 µl µl µl µl Alcohol pyramidon Phenolphthalein Table 2. Results of alcohol pyramidon or phenolphthalein for 5 test tubes containing 2, 1, 0.5, 0.25 and µl blood samples in test tubes containing about 1 ml stool sample mixed with 3 mls distilled water Amount of blood 2 µl 1 µl 0.5 µl 0.25 µl µl Alcohol pyramidon Phenolphthalein Table 3. Results of detection of fecal occult blood using alcohol pyramidon and phenolphthalein methods in 100 stool samples with order for occult blood test Results of the tests Negative 4+positive 3+positive 2+positive 1+positive Alcohol pyramidon Phenolphthalein
4 In this research the sensitivity of phenolphthalein method was determined by estimation of minimum amount of blood which can be detected in 1 ml fecal samples. Considering this fact that the consistency of fecal samples is not constant in all patients, so estimation of occult blood in 1 ml feces is not a standard method and there may be some variation among different patients. This was a one of the leading limitation of this research. However, in practice there is no alternative method to overcome this limitation. According to recent estimates, about 8.2 million deaths and 14.1 million new cancer cases occurred in 2012 worldwide and over the years, the burden of cancer has shifted to developing countries [26]. Colorectal cancer with over 1.2 million new cancer cases and 608,700 deaths in 2008 is the third most commonly diagnosed cancer in males and the second in females [27]. In the time period the rate of colorectal cancer per populations were 4.1 in India to 59.1 in Czech among men and 3.6 in India to 39.9 in New Zealand among females [28]. Screening measures lowers colorectal cancer mortality by detecting tumors at earlier stages [29-31]. In the United States the increased use of screening measures has been considered as one of the most important factors responsible for the recent decline in colorectal cancer rates [32,33]. Considering importance of screening methods for prevention from colorectal cancer, it seems that phenolphthalein method described in this study is an appropriate method for screening colorectal cancer especially in developing countries. 5. CONCLUSION Phenolphthalein method is a sensitive, simple and low price test for screening of colorectal cancer especially in low income countries which can be performed easily not only in diagnostic labs but also at home by patients. CONSENT As per international standard or university standard, patient s written consent has been collected and preserved by the authors. ETHICAL APPROVAL As per international standard or university standard, written approval of Ethics committee has been collected and preserved by the authors. ACKNOWLEDGEMENT This work was financially supported by grant from Isfahan university of medical sciences. COMPETING INTERESTS Authors have declared that no competing interests exist. REFERENCES 1. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. New England Journal of Medicine. 2012; 366(25): Greegor DH. Diagnosis of large-bowel cancer in the asymptomatic patient. Jama. 1967;201(12): Greegor DH. Detection of silent colon cancer in routine examination. CA: A Cancer Journal for Clinicians. 1969;19(6): Greegor DH. Occult blood testing for detection of asymptomatic colon cancer. Cancer. 1971;28(1): Greegor DH. Detection of colorectal cancer using guaiac slides. CA: A Cancer Journal for Clinicians. 1972;22(6): Hastings JB. Mass screening for colorectal cancer. The American Journal of Surgery. 1974;127(2): Stroehlein JR, Fairbanks VF, McGill DB, Go VL. Hemoccult detection of fecal occult blood quantitated by radioassay. Digestive Diseases and Sciences. 1976;21(10): Winawer SJ. Fecal occult blood testing. Digestive Diseases and Sciences. The American Journal of Digestive Diseases. 1976;21(10): Bertario L, Russo A, Crosignani P, Sala P, Spinelli P, Pizzetti P, et al. Reducing colorectal cancer mortality by repeated faecal occult blood test: A nested case control study. European Journal of Cancer. 1999;35(6): Faivre J, Tazi M, ElMrini T, Lejeune C, Benhamiche A, Dassonville F. Faecal occult blood screening and reduction of 4
5 colorectal cancer mortality: A case-control study. British Journal of Cancer. 1999; 79(3-4): Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised study of screening for colorectal cancer with faecaloccult-blood test. The Lancet. 1996; 348(9040): Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. New England Journal of Medicine. 1993; 328(19): Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: Effectiveness of biennial screening for fecal occult blood. Journal of the National Cancer Institute. 1999;91(5): Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. New England Journal of Medicine. 2000; 343(22): Hope R, Chu G, Hope A, Newcombe R, Gillespie P, Williams S. Comparison of three faecal occult blood tests in the detection of colorectal neoplasia. Gut. 1996;39(5): John DJBS, Young GP, Alexeyeff MA, Deacon MC, Cuthbertson AM, Macrae FA, et al. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology. 1993;104(6): Zhou D, Feng F, Zhang Y, Lai Z, Zhang W, Li L, et al. Comparison of Shams' test for rectal mucus to an immunological test for fecal occult blood in large intestinal carcinoma screening. Analysis of a checkup of 6480 asymptomatic subjects. Chinese Medical Journal. 1993;106(10): Demers RY, Stawick LE, Demers P. Relative sensitivity of the fecal occult blood test and flexible sigmoidoscopy in detecting polyps. Preventive medicine. 1985;14(1): Illingworth D. Influence of diet on occult blood tests. Gut. 1965;6(6): Barnett RN. The guaiac test: correlation with clinical findings. Gastroenterology. 1952;21(4): Markman HD. Errors in the guaiac test for occult blood. JAMA. 1967;202(8): Van Rossum LG, Van Rijn AF, Laheij RJ, Van Oijen MG, Fockens P, Van Krieken HH, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008;135(1): Needham C, Simpson R. The benzidine test for occult blood in faeces. QJM. 1952;21(2): Deadman N. Evaluation of chromogens suitable for occult blood in faeces. Clinica Chimica Acta. 1971;35(2): Young GP, St John DJB, Winawer SJ, Rozen P. Choice of fecal occult blood tests for colorectal cancer screening: Recommendations based on performance characteristics in population studies. The American Journal of Gastroenterology. 2002;97(10): Torre LA, Bray F, Siegel RL, Ferlay J, Lortet Tieulent J, Jemal A. Global cancer statistics. CA: A Cancer Journal for Clinicians. 2015;65(2): Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A cancer Journal for Clinicians. 2011;61(2): Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA: A Cancer Journal for Clinicians. 2009;59(6): Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer. Annals of Internal Medicine. 2009;150(1): Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): An update. The American Journal of Gastroenterology. 2008;103(6): Walsh JM, Terdiman JP. Colorectal cancer screening: scientific review. Jama. 2003; 289(10): Espey DK, Wu XC, Swan J, Wiggins C, Jim MA, Ward E, et al. Annual report to the nation on the status of cancer, , featuring cancer in American Indians and Alaska Natives. Cancer. 2007;110(10):
6 33. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi Society Task Force on Colorectal Cancer, and the American College of Radiology. CA: A Cancer Journal for Clinicians. 2008; 58(3): Sharafi et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Peer-review history: The peer review history for this paper can be accessed here: 6
The effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an open-label, randomized controlled trial
Page1 of 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 The effectiveness of telephone reminders and SMS messages on compliance with colorectal cancer screening: an
More informationTHE EFFECT OF FECAL OCCULT-BLOOD SCREENING ON THE INCIDENCE OF COLORECTAL CANCER
THE EFFECT OF FECAL OCCULT-BLOOD SCREENING ON THE INCIDENCE OF COLORECTAL CANCER JACK S. MANDEL, PH.D., M.P.H., TIMOTHY R. CHURCH, PH.D., JOHN H. BOND, M.D., FRED EDERER, M.A., MINDY S. GEISSER, M.S.,
More informationCitation for published version (APA): Wijkerslooth de Weerdesteyn, T. R. (2013). Population screening for colorectal cancer by colonoscopy
UvA-DARE (Digital Academic Repository) Population screening for colorectal cancer by colonoscopy de Wijkerslooth, T.R. Link to publication Citation for published version (APA): Wijkerslooth de Weerdesteyn,
More informationSarvenaz Moosavi, 1 Robert Enns, 1 Laura Gentile, 2 Lovedeep Gondara, 2 Colleen McGahan, 2 and Jennifer Telford Introduction
Canadian Gastroenterology and Hepatology Volume 2016, Article ID 5914048, 5 pages http://dx.doi.org/10.1155/2016/5914048 Research Article Comparison of One versus Two Fecal Immunochemical Tests in the
More informationEarly detection and screening for colorectal neoplasia
Early detection and screening for colorectal neoplasia Robert S. Bresalier Department of Gastroenterology, Hepatology and Nutrition. The University of Texas. MD Anderson Cancer Center. Houston, Texas U.S.A.
More informationEstimation of screening test (Hemoccult ) sensitivity in colorectal cancer mass screening
doi: 1.154/ bjoc.21.1752, available online at http://www.idealibrary.com on http://www.bjcancer.com Estimation of screening test (Hemoccult ) sensitivity in colorectal cancer mass screening JL Jouve 1,
More informationRESEARCH INTRODUCTION
Effect of repeated invitations on uptake of colorectal cancer screening using faecal occult blood testing: analysis of prevalence and incidence screening R J C Steele, professor of surgery, 1,2 I Kostourou,
More informationPROCEDURE MANUAL. Prepared By Date Adopted Supersedes Procedure # Review Date Revision Date Signature
Lab Name: Procedure #: Procedure: CLIA Complexity: WAIVED Prepared By Date Adopted Supersedes Procedure # Review Date Revision Date Signature Distributed to # of Copies Distributed to # of Copies This
More informationDebate: General surveillance/screening for colon cancer in a resource constrained environment is imperative
Debate: General surveillance/screening for colon cancer in a resource constrained environment is imperative Dr. Meryl Oyomno Department of surgery, University of Pretoria INTRODUCTION Screening is the
More informationColorectal Cancer Screening What are my options?
069-Colorectal cancer (Rosen) 1/23/04 12:59 PM Page 69 What are my options? Wayne Rosen, MD, FRCSC As presented at the 37th Annual Mackid Symposium: Cancer Care in the Community (May 22, 2003) There are
More informationColorectal cancer screening
26 Colorectal cancer screening BETHAN GRAF AND JOHN MARTIN Colorectal cancer is theoretically a preventable disease and is ideally suited to a population screening programme, as there is a long premalignant
More informationEarlier stages of colorectal cancer detected with immunochemical faecal occult blood tests
O R I G I N A L A R T I C L E Earlier stages of colorectal cancer detected with immunochemical faecal occult blood tests L.G.M. van Rossum 1*, A.F. van Rijn 2, I.P. van Munster 3, J.B.M.J. Jansen 1, P.
More informationPerformance Characteristics and Comparison of Two Fecal Occult Blood Tests in Patients Undergoing Colonoscopy
Dig Dis Sci (2007) 52:1009 1013 DOI 10.1007/s10620-006-9383-y ORIGINAL ARTICLE Performance Characteristics and Comparison of Two Fecal Occult Blood Tests in Patients Undergoing Colonoscopy Marcia Cruz-Correa
More informationAntithrombotics During Fecal Occult Blood Testing: A Meta-Analysis And Systematic Review
ISPUB.COM The Internet Journal of Gastroenterology Volume 13 Number 1 Antithrombotics During Fecal Occult Blood Testing: A Meta-Analysis And Systematic Review I Ashraf, S Paracha, S Paracha, M Arif, A
More informationOptimizing implementation of fecal immunochemical testing in Ontario: A randomized controlled trial
Optimizing implementation of fecal immunochemical testing in Ontario: A randomized controlled trial J. Tinmouth, N.N. Baxter, L.F. Paszat, E. Randell, M. Serenity, R. Sutradhar, L. Rabeneck Conflicts of
More informationEXTRA PROBLEM 4: SCREENING FOR COLORECTAL CANCER
EXTRA PROBLEM 4: SCREENING FOR COLORECTAL CANCER The fecal occult blood test, widely used both in physicians offices and at home to screen patients for colon and rectal cancer, examines a patient s stool
More informationFREQUENTLY ASKED QUESTIONS
FREQUENTLY ASKED QUESTIONS What is CRC? CRC (CRC) is cancer of the large intestine (colon), the lower part of the digestive system. Rectal cancer is cancer of the last several inches of the colon. Together,
More informationC olorectal adenomas are reputed to be precancerous
568 COLORECTAL CANCER Incidence and recurrence rates of colorectal adenomas estimated by annually repeated colonoscopies on asymptomatic Japanese Y Yamaji, T Mitsushima, H Ikuma, H Watabe, M Okamoto, T
More informationJoint Session with ACOFP and Cancer Treatment Centers of America (CTCA): Cancer Screening: Consensus & Controversies. Ashish Sangal, M.D.
Joint Session with ACOFP and Cancer Treatment Centers of America (CTCA): Cancer Screening: Consensus & Controversies Ashish Sangal, M.D. Cancer Screening: Consensus & Controversies Ashish Sangal, MD Director,
More informationCOLORECTAL CANCER SCREENING &THE FECAL IMMUNOCHEMICAL TEST (FIT) MATHEW ESTEY, PHD, FCACB CLINICAL CHEMIST
COLORECTAL CANCER SCREENING &THE FECAL IMMUNOCHEMICAL TEST (FIT) MATHEW ESTEY, PHD, FCACB CLINICAL CHEMIST MATHEW.ESTEY@DYNALIFEDX.COM FACULTY /PRESENTER DISCLOSURE FACULTY: MATHEW ESTEY RELATIONSHIPS
More informationSCREENING FOR COLON AND RECTAL CANCER
Review Article SCREENING FOR COLON AND RECTAL CANCER Jack S. Mandel, PhD, MPH School of Public Health, University of Minnesota Introduction Approximately 138,200 new cases and 55,300 deaths occured in
More informationGet tested for. Colorectal cancer. Doctors know how to prevent colon or rectal cancer- and you can, too. Take a look inside.
Get tested for Colorectal cancer Doctors know how to prevent colon or rectal cancer- and you can, too. Take a look inside. 1 If you re 50 or older, you need to get tested for colorectal cancer. It s one
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Vol 120 No 1258 ISSN 1175 8716 A survey of colonoscopy capacity in New Zealand s public hospitals Andrew Yeoman, Susan Parry Abstract Aims Population screening for colorectal
More informationScreening for Colon Cancer
Screening for Colon Cancer What is colon cancer? The colon is the last few feet of your digestive system. Colon cancer happens when cells that are not normal grow in your colon. These cancers usually begin
More informationThe Canadian Cancer Society estimates that in
How Do I Screen For Colorectal Cancer? By Ted M. Ross, MD, FRCS(C); and Naomi Ross, RD, BSc To be presented at the University of Toronto s Primary Care Today sessions (October 3, 2003) The Canadian Cancer
More informationGlobal colorectal cancer screening appropriate or practical? Graeme P Young, Flinders University WCC, Melbourne
Global colorectal cancer screening appropriate or practical? Graeme P Young, Flinders University. 2014 WCC, Melbourne Outline WHO criteria to justify screening Appropriateness: Global variation in incidence
More informationImproving Outcomes in Colorectal Cancer: The Science of Screening. Colorectal Cancer (CRC)
Improving Outcomes in Colorectal Cancer: The Science of Screening Tennessee Primary Care Association October 23, 2014 Durado Brooks, MD, MPH Director, Prostate and Colorectal Cancers Colorectal Cancer
More informationFaecal Immunochemical Testing (FIT) for Screening and Symptomatic Patients
Faecal Immunochemical Testing (FIT) for Screening and Symptomatic Patients Caroline Addison NE BCSP Hub Director and Consultant Clinical Scientist What is FIT Type of Faecal Occult Blood test Designed
More informationFECAL OCCULT BLOOD TEST
MEDICAL POLICY For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS FECAL OCCULT BLOOD TEST Policy Number: CMP - 023 Effective Date: January 1, 2018 Table
More informationColorectal cancer (CRC) is the second leading cause ORIGINAL RESEARCH
ORIGINAL RESEARCH Annals of Internal Medicine Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening A Retrospective Cohort Study Christopher D. Jensen, PhD, MPH; Douglas A. Corley,
More informationR. J. L. F. Loffeld, 1 P. E. P. Dekkers, 2 and M. Flens Introduction
ISRN Gastroenterology Volume 213, Article ID 87138, 5 pages http://dx.doi.org/1.1155/213/87138 Research Article The Incidence of Colorectal Cancer Is Decreasing in the Older Age Cohorts in the Zaanstreek
More informationRandomised study of screening for colorectal cancer with faecaloccult-blood
Articles Randomised study of screening for colorectal cancer with faecaloccult-blood test Ole Kronborg, Claus Fenger, Jørn Olsen, Ole Dan Jørgensen, Ole Søndergaard Summary Background Case-control studies
More informationScreening for Colorectal Neoplasms With New Fecal Occult Blood Tests: Update on Performance Characteristics
ARTICLE Screening for Colorectal Neoplasms With New Fecal Occult Blood Tests: Update on Performance Characteristics James E. Allison, Lori C. Sakoda, Theodore R. Levin, Jo P. Tucker, Irene S. Tekawa, Thomas
More informationThe New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean?
The New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean? Robert A. Smith, PhD Cancer Control, Department of Prevention and Early Detection American Cancer Society
More informationRecommendations on Screening for Colorectal Cancer 2016
Recommendations on Screening for Colorectal Cancer 2016 Canadian Task Force on Preventive Health Care (CTFPHC) Putting Prevention into Practice Canadian Task Force on Preventive Health Care Groupe d étude
More informationC olorectal cancer (CRC) is the second most common
CANCER Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial J H Scholefield, S Moss, F Sufi, C M Mangham, J D Hardcastle... See end of
More informationGrand Rounds. Des Moines University. May 5, Durado Brooks, MD, MPH Director, Cancer Control Intervention American Cancer Society
Grand Rounds Des Moines University May 5, 2016 Durado Brooks, MD, MPH Director, Cancer Control Intervention American Cancer Society Case Summary Mrs. J is a 56 y o w female complaining of always tired;
More informationC olorectal cancer (CRC) is one of the leading causes of
1329 COLON Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure
More informationShould you have a test to screen for Bowel Cancer?
Should you have a test to screen for Bowel Cancer? Making Decisions: Choices for Men Aged 55-64 years MaleBooklet_Steps_withQs.indd 1 3/3/08 1:42:40 PM This booklet was developed by members of the Screening
More informationReferences. Valorization
Valorization 179 Valorization 180 Valorization Colorectal cancer (CRC) is a major burden on the health care system with over 1,4millionnewlydiagnosedpatientsandalmost700,000deathsannually. 1 Becauseof
More informationFecal occult blood tests: a cost-effectiveness analysis Gyrd-Hansen D
Fecal occult blood tests: a cost-effectiveness analysis Gyrd-Hansen D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract
More informationColorectal Cancer Screening
Colorectal Cancer Screening Jennifer A. Inra, MD, and Ramona Lim, MD Abstract Colorectal cancer (CRC) is a common malignancy among both women and men, and the risk increases with increasing age. The incidence
More informationACS Colorectal Cancer Screening Guideline for Average Risk Adults 2018
ACS Colorectal Cancer Screening Guideline for Average Risk Adults 2018 1 How are Cancer Screening Guidelines Developed? ACS Guideline Development Process Systematic Evidence Review & Modeling Reports [existing
More informationResearch Article Development of Polyps and Cancer in Patients with a Negative Colonoscopy: A Follow-Up Study of More Than 20 Years
ISRN Gastroenterology, Article ID 261302, 4 pages http://dx.doi.org/10.1155/2014/261302 Research Article Development of Polyps and Cancer in Patients with a Negative Colonoscopy: A Follow-Up Study of More
More informationCombination of Sigmoidoscopy and a Fecal Immunochemical Test to Detect Proximal Colon Neoplasia
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1341 1346 Combination of Sigmoidoscopy and a Fecal Immunochemical Test to Detect Proximal Colon Neoplasia JUN KATO,* TAMIYA MORIKAWA,* MOTOAKI KURIYAMA,*
More informationGuidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer
Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer David A. Lieberman, 1 Douglas K. Rex, 2 Sidney J. Winawer,
More informationJohn Croese, Stephen Fairley, John Masson. Gastroenterology, Townsville Hospital, Queensland. School of Population Health, University of Queensland
Guaiac versus immunochemical tests: faecal occult blood test screening for colorectal cancer in a rural community Abstract Objective: To describe patient participation and clinical performance in a colorectal
More informationWellness Along the Cancer Journey: Cancer Types Revised October 2015 Chapter 4: Colorectal Cancer Overview
Wellness Along the Cancer Journey: Cancer Types Revised October 2015 Chapter 4: Colorectal Cancer Overview Cancer Types Rev. 10.20.15 Page 35 Colorectal Cancer Overview Group Discussion True False Not
More informationScreening for colorectal cancer
Postgrad Med J (1994) 70, 469-474 A) The Fellowship of Postgraduate Medicine, 1994 Review Article Screening for colorectal cancer D.H. Bennett and J.D. Hardcastle Department ofsurgery, E Floor, West Block,
More informationScreening for Colorectal Cancer
clinical practice Screening for Colorectal Cancer David A. Lieberman, M.D. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies
More informationAppendix 1: Description of the 25 studies excluded from the meta-analysis of Sensitivity
Supplementary Data Appendix 1: Description of the 25 studies excluded from the meta-analysis of Sensitivity and Specificity. Below we list each study excluded from our meta-analysis of the sensitivity
More informationColorectal Cancer Screening. Dr Kishor Muniyappa 2626 Care Drive, Suite 101 Tallahassee, FL Ph:
Colorectal Cancer Screening Dr Kishor Muniyappa 2626 Care Drive, Suite 101 Tallahassee, FL 32308 Ph: 850-297-0351 What we ll be talking about How common is colorectal cancer? What is colorectal cancer?
More informationColorectal Cancer Screening in Ohio CHCs. Ohio Association of Community Health Centers
Colorectal Cancer Screening in Ohio CHCs Ohio Association of Community Health Centers 2 1/29/2015 Your Speakers Dr. Ted Wymyslo Ashley Ballard Randy Runyon 3 1/29/2015 Facts 3 rd most common cancer in
More informationColorectal Cancer Screening and Surveillance
1 Colorectal Cancer Screening and Surveillance Jeffrey Lee MD, MAS Assistant Clinical Professor of Medicine University of California, San Francisco jeff.lee@ucsf.edu Objectives Review the various colorectal
More informationRecommendations About Screening
36 Recommendations About Screening Alba DiCenso and Gordon Guyatt The following Editorial Board members also made substantive contributions to this chapter: Susan Marks, Andrea Nelson, and Mark Newman.
More informationBACKGROUND. Fecal immunochemical tests (FIT) are an advanced fecal occult. METHODS. Individuals sampled consecutive stools, at home, with both FIT and
2152 Comparison of a Brush-Sampling Fecal Immunochemical Test for Hemoglobin With a Sensitive Guaiac-Based Fecal Occult Blood Test in Detection of Colorectal Neoplasia Alicia Smith 1,2 Graeme P. Young,
More informationTransition to Fecal Immunochemical Testing (FIT)
Transition to Fecal Immunochemical Testing (FIT) Frequently Asked Questions for Primary Care Providers October 2017 Version 1.1 Overview Ontario will be transitioning from the guaiac fecal occult blood
More informationIEHP UM Subcommittee Approved Authorization Guidelines Colorectal Cancer Screening with Cologuard TM for Medicare Beneficiaries
for Medicare Beneficiaries Policy: Based on our review of the available evidence, the IEHP UM Subcommittee adopts the use of Cologuard TM - a multi-target stool DNA test as a colorectal cancer screening
More informationIntroduction. Abstract
CHAPTER 6 Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: Faecal Immunochemical Test versus Guaiacbased Faecal Occult Blood Test J.S. Terhaar sive Droste [1], FA. Oort
More informationCLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING
CLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING This guideline is designed to assist practitioners by providing the framework for colorectal cancer (CRC) screening, and is not intended to replace
More informationCite this article as: BMJ, doi: /bmj c (published 5 July 2004)
Cite this article as: BMJ, doi:10.1136/bmj.38153.491887.7c (published 5 July 2004) Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom UK Colorectal
More informationFrequency of Diagnosis of Colorectal Cancer with Double Contrast Barium Enema
Bahrain Medical Bulletin, Vol.24, No.3, September 2002 Frequency of Diagnosis of Colorectal Cancer with Double Contrast Barium Enema Najeeb S Jamsheer, MD, FRCR* Neelam. Malik, MD, MNAMS** Objective: To
More informationColorectal Cancer Screening. Paul Berg MD
Colorectal Cancer Screening Paul Berg MD What is clinical integration? AMA Definition The means to facilitate the coordination of patient care across conditions, providers, settings, and time in order
More informationLIPPINCOTT WILLIAMS AND WILKINS
AUTHOR QUERY FORM LIPPINCOTT WILLIAMS AND WILKINS JOURNAL NAME: MCG ARTICLE NO: JCG66 QUERIES AND / OR REMARKS QUERY NO. Details Required Author s Response GQ Q Q2 Q Please confirm that givennames (coloured
More informationSetting The setting was secondary care. The economic study was carried out in Australia.
Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy O'Leary B A, Olynyk J K, Neville A M, Platell C F
More informationThe choice of methods for Colorectal Cancer Screening; The Dutch experience
The choice of methods for Colorectal Cancer Screening; The Dutch experience Monique van Leerdam, Gastroenterologist, NKI-AVL, Amsterdam The Netherlands Colorectal cancer CRC 2 nd cause of cancer related
More informationOptimal Colonoscopy Surveillance Interval after Polypectomy
REVIEW Clin Endosc 2016;49:359-363 http://dx.doi.org/10.5946/ce.2016.080 Print ISSN 2234-2400 On-line ISSN 2234-2443 Open Access Optimal Colonoscopy Surveillance Interval after Polypectomy Tae Oh Kim Department
More informationGUAIAC tests for fecal occult blood detect the pseudoperoxidase
Vol. 334 No. 3 COMPARISON OF FECAL OCCULT-BLOOD TESTS FOR COLORECTAL-CANCER SCREENING 155 A COMPARISON OF FECAL OCCULT-BLOOD TESTS FOR COLORECTAL-CANCER SCREENING JAMES E. ALLISON, M.D., IRENE S. TEKAWA,
More informationColorectal Cancer Screening and Risk Assessment Workflow. Documentation Guide for Health Center NextGen Users
Colorectal Cancer Screening and Risk Assessment Workflow Documentation Guide for Health Center NextGen Users Colorectal Cancer Screening and Risk Assessment Workflow and Documentation Guide for Health
More informationn engl j med 366;25 nejm.org june 21,
The new england journal of medicine established in 1812 june 21, 2012 vol. 366 no. 25 Colorectal-Cancer Incidence and Mortality with Flexible Sigmoidoscopy Robert E. Schoen, M.D., M.P.H., Paul F. Pinsky,
More informationObjectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background
Colorectal Cancer Screening Payam Afshar, MS, MD Kaiser Permanente, San Diego Objectives Colorectal cancer background Colorectal cancer screening populations Colorectal cancer screening modalities Colonoscopy
More informationColorectal Cancer Screening: Technical Report Prepared for the National Commission on Prevention Priorities
Colorectal Cancer Screening: Technical Report Prepared for the National Commission on Prevention Priorities Version 06.1; last updated May 11, 2006 Prepared by Michael V. Maciosek, PhD* Leif I. Solberg,
More informationCRC Risk Factors. U.S. Adherence Rates Cancer Screening. Genetic Model of Colorectal Cancer. Epidemiology and Clinical Consequences of CRC
10:45 11:45 am Guide to Colorectal Cancer Screening SPEAKER Howard Manten M.D. Presenter Disclosure Information The following relationships exist related to this presentation: Howard Manten MD: No financial
More informationColorectal cancer screening
Singapore Med J 2017; 58(1): 24-28 doi: 10.11622/smedj.2017004 CMEArticle Colorectal cancer screening Pak Wo Webber Chan 1, MBBS, MRCP, Jing Hieng Ngu 1,2, MBChB, FRACP, Zhongxian Poh 3, MBBS, MRCP, Roy
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Journal of the New Zealand Medical Association Colonoscopy requirements of population screening for colorectal cancer in New Zealand Terri Green, Ann Richardson, Susan Parry
More informationIncreasing Colorectal Cancer Screening in Wyoming. Allie Bain, MPH Outreach & Education Supervisor Wyoming Integrated Cancer Services Program
Increasing Colorectal Cancer Screening in Wyoming Allie Bain, MPH Outreach & Education Supervisor Wyoming Integrated Cancer Services Program Overview What is colorectal cancer? What are risk factors for
More informationThere is No One Best CRC Screening Test: The Proof and the Benefits of Getting FIT
There is No One Best CRC Screening Test: The Proof and the Benefits of Getting FIT James E. Allison, MD, FACP, AGAF Clinical Professor of Medicine Emeritus University of California San Francisco Emeritus
More informationColorectal cancer screening in Asia
Published Online January 8, 2013 Colorectal cancer screening in Asia Siew C. Ng * and Sunny H. Wong Institute of Digestive Disease, Department of Medicine and Therapeutics, Chinese University of Hong Kong,
More informationHealth Professional Information
Bowel Screening Wales Health Professional Information 2011 www.bowelscreeningwales.org.uk Version 2.0 Acknowledgements Bowel Screening Wales would like to express their sincere thanks to the English and
More informationCancer Screening 2009: New Tests, New Choices
Objectives Cancer Screening 2009: New Tests, New Choices UCSF Annual Review in Family Medicine April 21, 2009 Michael B. Potter, MD Professor, Clinical Family and Community Medicine UCSF School of Medicine
More informationT. Rubeca 1, S. Rapi 2, M. Confortini 1, M. Brogioni 2, G. Grazzini 1, M. Zappa 1, D. Puliti 1, G. Castiglione 1, S. Ciatto 1
The International Journal of Biological Markers, Vol. 21 no. 3, pp. 157-161 2006 Wichtig Editore Evaluation of diagnostic accuracy of screening by fecal occult blood testing (FOBT). Comparison of FOB Gold
More informationBackground and Rationale for Gipson bill AB The imperative for colonoscopy after a positive FOBT (Fecal Occult Blood Test)
Background and Rationale for Gipson bill AB 1763 The imperative for colonoscopy after a positive FOBT (Fecal Occult Blood Test) The Affordable Care Act (ACA) requires all private insurers (except grandfathered
More informationJournal of Clinical Laboratory Instruments and Reagents, Vol. 34, No. 3 (June, 2011) Supplement
Journal of Clinical Laboratory Instruments and Reagents, Vol. 34, No. 3 (June, 2011) Supplement Laboratory Instruments and Reagents 34(3): 387-392, 2011 Evaluation of the Extel Hemo Auto HS and the Hemo
More information1101 First Colonial Road, Suite 300, Virginia Beach, VA Phone (757) Fax (757)
1101 First Colonial Road, Suite 300, Virginia Beach, VA 23454 www.vbgastro.com Phone (757) 481-4817 Fax (757) 481-7138 1150 Glen Mitchell Drive, Suite 208 Virginia Beach, VA 23456 www.vbgastro.com Phone
More informationCerTest Turbilatex. A quantitative immunological latex method. FOB Calprotectin Transferrin H. pylori
CerTest Turbilatex A quantitative immunological latex method FOB Calprotectin Transferrin H. pylori Turbidimetric technique. A latex turbidimetric assay The turbidimetric assay is based on the agglutination
More informationCologuard Screening for Colorectal Cancer
Pending Policies - Medicine Cologuard Screening for Colorectal Cancer Print Number: MED208.056 Effective Date: 08-15-2016 Coverage: I.Cologuard stool DNA testing may be considered medically necessary for
More informationNHS KINGSTON. Contents
NHS KINGSTON Contents 1. Background... 2 2. Targets and quality standards... 2 3. Service provision and performance... 3 Uptake... 3 Investigations... 6 Cancer detection... 7 Age extension... 7 4. Quality
More informationColorectal Cancer Screening in Later Life: Blum Center Rounds
Colorectal Cancer Screening in Later Life: Blum Center Rounds OCTOBER 10, 2018 Agenda CRC Screening and Surveillance Recommendation Screening for Colon Cancer later in life Discussion and listening Families
More informationPre-formulated implementation intentions to promote colorectal cancer screening: a cluster-randomized trial
Lo, SH; Good, A; Sheeran, P; Baio, G; Rainbow, S; Vart, G; von Wagner, C; (2013) Preformulated Implementation Intentions to Promote Colorectal Cancer Screening: A Cluster- Randomized Trial. Health Psychology
More informationPapers. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, Hemoccult. Abstract.
A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, Hemoccult Bernie Towler, Les Irwig, Paul Glasziou, Jan Kewenter, David Weller, Chris Silagy Abstract
More informationFECAL OCCULT BLOOD TEST (FOBT) Common Guaiac versus Immunochemical Test
FECAL OCCULT BLOOD TEST (FOBT) Common Guaiac versus Immunochemical Test LIMBACH-LABORATORY H E I D E L B E R G H J Roth H Schmidt-Gayk Estimated incidence of cancer in Europe and European Union, 2006 Limbach
More informationInterval Fecal Immunochemical Testing in a Colonoscopic Surveillance Program Speeds Detection of Colorectal Neoplasia
GASTROENTEROLOGY 2010;139:1918 1926 Interval Fecal Immunochemical Testing in a Colonoscopic Surveillance Program Speeds Detection of Colorectal Neoplasia JOANNE M. LANE,*, ELIZABETH CHOW,*, GRAEME P. YOUNG,*,
More informationColorectal cancer screening A puzzle of tests and strategies
Colorectal cancer screening A puzzle of tests and strategies A. Van Gossum, MD, PhD Head of the Clinic of Intestinal Diseases and Nutritional Support Department of Gastroenterology Hôpital Erasme ULB -
More informationColorectal Cancer Screening: A Clinical Update
11:05 11:45am Colorectal Cancer Screening: A Clinical Update SPEAKER Kevin A. Ghassemi, MD Presenter Disclosure Information The following relationships exist related to this presentation: Kevin A. Ghassemi,
More informationColorectal cancer screening: Why immunochemical fecal occult blood tests may be the best option
Flitcroft et al. BMC Gastroenterology 2012, 12:183 DEBATE Open Access Colorectal cancer screening: Why immunochemical fecal occult blood tests may be the best option Kathy L Flitcroft *, Les M Irwig, Stacy
More information2. Describe pros/cons of screening interventions (including colonoscopy, CT colography, fecal tests)
Learning Objectives 1. Review principles of colon adenoma/cancer biology that permit successful prevention regimes 2. Describe pros/cons of screening interventions (including colonoscopy, CT colography,
More informationReferral Criteria for Direct Access Outpatient Colonoscopy or Computed Tomography Colonography
Referral Criteria for Direct Access Outpatient Colonoscopy or Computed Tomography Colonography 2019 Released 2019 health.govt.nz Citation: Ministry of Health. 2019. Referral Criteria for Direct Access
More informationCOLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION.
The West London Medical Journal 2009 Vol No 1 pp 23-31 COLORECTAL SCREENING PROGRAMME: IMPACT ON THE HOSPITAL S PATHOLOGY SERVICES SINCE ITS INTRODUCTION. Competing interests: None declared ABSTRACT Sarah
More information